

Puma Biotechnology

Earnings Call

Commercial Update



November 6, 2025

nerlynx[®]
(neratinib) tablets




Forward-Looking Safe-Harbor Statement

This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.




Puma's Pharmacy and Distributor Network



\$51.9 Million Net NERLYNX Revenue in Q3'25


~8% decrease in Q3'25 compared to Q3'24



Inventory Change (\$)

Q3'24	Q3'25
\$0.7 mil	\$3.1 mil

~6% increase in Q3'25 compared to Q2'25




Inventory Change (\$)

Q2'25	Q3'25
-\$1.3 mil	\$3.1 mil

2,949 Ex-Factory Bottles Were Sold in Q3'25


~8% increase in Q3'25 compared to Q3'24



Inventory Change Bottles

Q3'24	Q3'25
39	182

~13% increase in Q3'25 compared to Q2'25




Inventory Change Bottles

Q2'25	Q3'25
-85	182

~77% of Patients in Q3'25 Started at a Reduced Dose*

% of Patients Starting at Reduced Dose



*Reduced dose defined as fewer than 6 pills per day

Rest of World Partnerships – Timelines

Region	Partner	Regulatory Approvals	Commercial Launches
Australia / SE Asia		• 2019 – Ext. Adj. in Australia, Singapore • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand • 2022 – Ext. Adj. in the Philippines; mBC in Singapore • 2023 – mBC in Malaysia • 2024 – Ext. Adj. and mBC in Thailand	• 2020 – Singapore • 2021 – Malaysia, Brunei, New Zealand
Israel		• 2020 – Approved in Ext. Adj. and mBC	• 2020 – Launched
Canada		• 2019 – Ext. Adj. approved • 2021 – mBC approved	• 2020 – Launched
Latin America		• 2019 – Ext Adj in Argentina • 2020 – Ext. Adj in Chile, Ecuador; mBC in Argentina • 2021 – Ext Adj. and mBC in Peru; mBC in Chile; Ext. Adj. in Brazil • 2022 – Ext. Adj. in Mexico; mBC in Ecuador • 2023 – mBC in Colombia and Mexico • 2024 – mBC in Brazil	• 2020 – Argentina • 2021 – Chile and Peru • 2022 – Brazil • 2023 – Mexico and Colombia
Europe Greater China Middle East North and West Africa South Africa Turkey		• 2019 – Ext. Adj. EMA and Hong Kong • 2020 – Ext. Adj. in China, Taiwan • 2021 – mBC in Taiwan • 2023 – Ext. Adj. in Morocco, South Africa, and UAE • 2024 – Ext. Adj. in Syria, Saudi Arabia, Algeria, Turkey • Q3 2025 – Ext. Adj. in Lebanon	• 2019 – Germany, UK, Austria • 2020 – Sweden, Finland, Scotland, Switzerland, Denmark, HK • 2021 – China, Taiwan, Greece, Czech Republic, Luxembourg • 2022 – Ireland and Spain • 2023 – Slovakia • 2024 – Morocco, South Africa, UAE, Turkey, Saudi Arabia • Q1 2025 – Libya
South Korea		• 2021 – Ext. Adj. in S. Korea	• 2022 – Launched
Russia/CIS		• Distribution agreement executed	

Puma Biotechnology

Earnings Call

Commercial Update



November 6, 2025

nerlynx[®]
(neratinib) tablets

